Anti-CD154 mAB and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Muller, Yannick D ^a,b   Mai, Gang ^a,c   Morel, Philippe ^a   Serre Beinier, Véronique ^a   Gonelle Gispert, Carmen ^a   Yung, Gisella Puga ^b   Ehirchiou, Driss ^b   Wyss, Jean Christophe ^d   Bigenzahn, Sinda ^e   Irla, Magali ^f   Heusser, Christoph ^g   Golshayan, Déla ^d   Seebach, Jörg D ^b   Wekerle, Thomas ^e   Bühler, Leo H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b University Hospital and Medical Faculty ^*  (Switzerland)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CD40 LIGAND MONOCLONAL ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; RAPAMYCIN; STREPTOZOCIN; CD40 LIGAND; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLOW CYTOMETRY; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOID ORGAN; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; RAT; REGULATORY T LYMPHOCYTE; SPLEEN; STREPTOZOCIN DIABETES; TREATMENT RESPONSE; XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; C57BL MOUSE; DRUG EFFECT; IMMUNOLOGY; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; GRAFT SURVIVAL; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; RATS; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 77955909935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010352     Document Type: Article

References (39)

1. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M (2002) Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 14: 592-600.
2. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, et al. (1999) Requirement for Tcell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 5: 1303-1307.
3. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, et al. (1999) Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5: 1298-1302.
4. Snanoudj R, de Preneuf H, Creput C, Arzouk N, Deroure B, et al. (2006) Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 19: 693-704.
5. Golshayan D, Buhler L, Lechler RI, Pascual M (2007) From current immunosuppressive strategies to clinical tolerance of allografts. Transpl Int 20: 12-24.
6. Xia G, He J, Leventhal JR (2008) Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant 8: 298-306.
7. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, et al. (2007) In vitroexpanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 109: 827-835.
8. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, et al. (2008) Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 14: 88-92.
9. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133: 775-787.
10. Dijke IE, Weimar W, Baan CC (2008) Regulatory T cells after organ transplantation: Where does their action take place? Hum Immunol 69: 389-398.
11. Muller YD, Golshayan D, Ehirchiou D, Wekerle T, Seebach JD, et al. (2009) T regulatory cells in xenotransplantation. Xenotransplantation 16: 121-128.
12. Mai G, Bucher P, Morel P, Mei J, Bosco D, et al. (2005) Anti-CD154 mAb treatment but not recipient CD154 deficiency leads to long-term survival of xenogeneic islet grafts. Am J Transplant 5: 1021-1031.
13. Bucher P, Gang M, Morel P, Mathe Z, Bosco D, et al. (2005) Transplantation of discordant xenogeneic islets using repeated therapy with anti-CD154. Transplantation 79: 1545-1552.
14. Battaglia M, Stabilini A, Roncarolo MG (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105: 4743-4748.
15. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, et al. (2006) Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55: 40-49.
16. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, et al. (2009) Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58: 652-662.
17. Lages CS, Suffia I, Velilla PA, Huang B, Warshaw G, et al. (2008) Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J Immunol 181: 1835-1848.
18. Shevach EM (2008) Special regulatory T cell review: How I became a T suppressor/regulatory cell maven. Immunology 123: 3-5.
19. Ford ML, Larsen CP (2009) Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev 229: 294-306.
20. Arefanian H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, et al. (2010) Short- Term Administrations of a Combination of Anti-LFA-1 and Anti-CD154 Monoclonal Antibodies Induces Tolerance to Neonatal Porcine Islet Xenografts in Mice. Diabetes.
21. Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, et al. (2008) Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T cells. Diabetes.
22. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, et al. (2006) Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 55: 1571-1580.
23. Jarvinen LZ, Blazar BR, Adeyi OA, Strom TB, Noelle RJ (2003) CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation 76: 1375-1379.
24. D'Cruz LM, Klein L (2005) Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6: 1152-1159.
25. Zeiser R, Negrin RS (2008) Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 7: 458-462.
26. Bigenzahn S, Blaha P, Koporc Z, Pree I, Selzer E, et al. (2005) The role of nondeletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant 5: 1237-1247.
27. Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735.
28. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, et al. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59: 3128-3133.
29. Kurtz J, Wekerle T, Sykes M (2004) Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol 25: 518-523.
30. Waldmann H, Adams E, Fairchild P, Cobbold S (2008) Regulation and privilege in transplantation tolerance. J Clin Immunol 28: 716-725.
31. Dijke IE, Velthuis JH, Caliskan K, Korevaar SS, Maat AP, et al. (2007) Intragraft FOXP3 mRNA expression reflects antidonor immune reactivity in cardiac allograft patients. Transplantation 83: 1477-1484.
32. Wang S, Jiang J, Guan Q, Lan Z, Wang H, et al. (2008) Reduction of Foxp3- expressing regulatory T cell infiltrates during the progression of renal allograft rejection in a mouse model. Transpl Immunol 19: 93-102.
33. Haanstra KG, Wubben JA, Korevaar SS, Kondova I, Baan CC, et al. (2007) Expression patterns of regulatory T-cell markers in accepted and rejected nonhuman primate kidney allografts. Am J Transplant 7: 2236-2246.
34. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A (2007) CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J Exp Med 204: 735-745.
35. Jaeckel E, von Boehmer H, Manns MP (2005) Antigen-specific FoxP3- transduced T-cells can control established type 1 diabetes. Diabetes 54: 306-310.
36. Codarri L, Vallotton L, Ciuffreda D, Venetz JP, Garcia M, et al. (2007) Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL- 7Ralphahigh cell population in solid organ transplant recipients. J Exp Med 204: 1533-1541.
37. Graca L, Cobbold SP, Waldmann H (2002) Identification of regulatory T cells in tolerated allografts. J Exp Med 195: 1641-1646.
38. Jovanovic V, Lair D, Soulillou JP, Brouard S (2008) Transfer of tolerance to heart and kidney allografts in the rat model. Transpl Int 21: 199-206.
39. Chauhan SK, Saban DR, Lee HK, Dana R (2009) Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol 182: 148-153.